Skip to content

Sinopharm Says New Protein Booster Works Better Against Omicron

  • New shot elicits higher antibodies against infectious variant
  • Inactivated shot offered weak protection even with booster

China’s state-owned vaccine maker Sinopharm said its new protein subunit Covid-19 inoculation offers better protection as a booster against the omicron variant than its widely deployed inactivated shot.

The vaccine, which contains parts of the virus’ spike protein, is found to be seven times more potent in stimulating protective antibodies against omicron compared to its older shot if deployed six months after two doses of the inactivated inoculation, according to a yet to be peer-reviewed study involving 1,800 participants in the UAE, where it is already approved.